TOT BIOPHARM International Co. Ltd. (HK:1875) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
TOT BIOPHARM International Co. Ltd. reported a substantial 49% increase in revenue for the first nine months of 2024, reaching RMB809,021 thousand, driven by robust sales of its self-developed products and CDMO/CMO services. The company also turned profitable, posting a net profit of RMB35,403 thousand compared to a loss in the same period last year. Investors should note that the results are unaudited and may fluctuate in future periods.
For further insights into HK:1875 stock, check out TipRanks’ Stock Analysis page.